SCHEMBL2903324

SCHEMBL2903324

Cc1ccc(CN2CCN(C=CC(=O)c3c(F)cccc3F)CC2)cc1C

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.52
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
HTT P42858 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPK1 P28482 1/20 0.44
GPR183 P32249 1/20 0.44
DRD2 P14416 2/20 0.42
DRD4 P21917 2/20 0.42
POLB P06746 1/20 0.40
CASP3 P42574 1/20 0.40
RAB9A P51151 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2903733 0.88 ALDH1A1 (0.60) FAAHKDM4EALDH1A1HTTMEN1
SCHEMBL2905864 0.87 KDM4E (0.58) FAAHKDM4EALDH1A1HTTMEN1
SCHEMBL2906206 0.87 ALDH1A1 (0.48) FAAHKDM4EALDH1A1HTTMEN1
SCHEMBL2902827 0.85 FAAH (0.51) FAAHMEN1KMT2AGPR183
SCHEMBL2908745 0.84 DRD4 (0.49) FAAHKDM4EALDH1A1HTTMEN1
SCHEMBL2909991 0.83 KDM4E (0.57) FAAHKDM4EALDH1A1HTTMEN1
SCHEMBL2908298 0.83 ALDH1A1 (0.54) KDM4EALDH1A1HTTMEN1KMT2A
SCHEMBL2908648 0.80 ALDH1A1 (0.52) KDM4EALDH1A1HTTMEN1KMT2A
SCHEMBL2903325 0.76 GPR183 (0.61) FAAHKDM4EALDH1A1HTTGPR183
SCHEMBL2905333 0.75 OPRM1 (0.52) FAAHMEN1KMT2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041104-B1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PF MEDICAMENT (FR) 2010-08-18 EP claimed
US-20090176803-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS PIERRE FABRE MEDICAMENT (FR) 2009-07-09 US claimed
EP-2041104-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS Pierre Fabre Medicament (FR) 2009-04-01 EP claimed
WO-2007147824-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PIERRE FABRE MEDICAMENT (FR) 2007-12-27 WO claimed
EP-2041104-B1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS PF MEDICAMENT (FR) 2010-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176803-A1 CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS F2R, F2RL1, F2RL3 FAAH 506/4885KDM4E 3494/4885ALDH1A1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.